Trials / Terminated
TerminatedNCT04443257
REassessement After Hospitalization for Sars-COV-2 disordER
REassessement After Hospitalization for Sars-COV-2 Infection : Standardized Assessment of Sequelae and Comorbidities 3 to 6 Months After Hospitalization
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 119 (actual)
- Sponsor
- University Hospital, Montpellier · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Currently, the sequelae and short-term medical and psychological impact of the sars-cov-2 infection ("CoVID-19") remain poorly described. The clinical and functional sequelae that may persist after acute sars-cov-2 ("CoVID-19") infection are essential to explore, in order to ensure the best possible follow-up of patients after discharge from hospital.
Detailed description
Since sars-cov-2 ("CoVID-19") is a newly defined infection, its sequelae and short-term medical and psychological impact remain poorly described.The clinical and functional sequelae that may persist after acute sars-cov-2 ("CoVID-19") infection are essential to explore, in order to ensure the best possible follow-up of patients after discharge from hospital. Indeed, some patients may develop chronic respiratory failure, pulmonary fibrosis, or other comorbidities including cardiovascular or metabolic diseases. The psychological impact is also essential to assess. The sequelae and comorbidities of patients could also vary depending on the severity of the initial acute involvement. Investigators propose to explore the sequelae of patients who have been hospitalized for acute sars-cov-2 infection, between 3 to 6 months after discharge from hospital, by characterizing the incidence of chronic respiratory failure and fibrosis, as well as of various comorbidities such as cardiovascular, metabolic, and psychological diseases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | assessment of the sequelae after hospitalization for Sars-COV-2 | the incidence of chronic respiratory failure and fibrosis, as well as of comorbidities including cardiovascular, metabolic, renal, hepatic, neurological, and psychological diseases |
Timeline
- Start date
- 2020-07-08
- Primary completion
- 2022-02-18
- Completion
- 2022-02-18
- First posted
- 2020-06-23
- Last updated
- 2023-02-21
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04443257. Inclusion in this directory is not an endorsement.